SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is facing intense debate among traders as the community splits between long-term believers citing the ecosystem's expanding utility and critics who label it an stagnant, speculative meme coin. Sentiment is heavily divided, with supporters anticipating massive price appreciation through supply burns while skeptics emphasize the token's massive circulating supply and lackluster performance compared to its all-time highs.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors weigh the upcoming launch of the Truth API against ongoing volatility and polarizing political discourse surrounding the company. The community remains deeply divided, with discussions ranging from intense speculation over potential price movements and platform monetization to heated debates regarding the company's long-term viability and its association with political events.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is generating significant community interest as a leading Real-World Asset (RWA) project, with investors closely watching its potential for institutional adoption alongside regulatory developments like the Clarity Act. Discussion is centered on the token's current role in governance versus the broader ecosystem's growth, as holders look forward to potential future value-accrual mechanisms and long-term scaling in the tokenized securities market.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

ALOY is trending as investors bet on its strategic role in building a U.S. domestic rare-earth supply chain ahead of upcoming federal mandates that will restrict dependence on Chinese materials. The community remains highly active, balancing long-term optimism regarding defense-sector contracts and institutional backing against concerns over share dilution, short-selling volatility, and recent price pullbacks.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as the community actively debates its price action and future potential relative to other established meme coins in the sector. Investors are expressing mixed sentiment, with some highlighting the token's cultural staying power and accumulation opportunities while others weigh in on the broader volatility affecting the meme crypto market.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly anticipate upcoming Phase 3 IZAR-1 trial results, with community members actively discussing potential best-in-class efficacy and a possible M&A catalyst. Market participants are closely watching for a weekend data release, drawing parallels between the firm's strategic positioning and recent sector acquisitions while highlighting the company's strong institutional backing.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is trending following a major partnership with Tesla and Renew Home to create a massive virtual power plant, which aims to provide flexible energy capacity to AI data centers and utilities. The community is actively debating the stock's future, weighing this potential for grid-scale infrastructure expansion against ongoing concerns regarding high interest rates, significant debt, and intense short selling.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuum is generating significant investor buzz as it makes its market debut, with the community closely tracking its valuation and potential as a leader in full-stack quantum computing. While supporters highlight institutional backing and the companys strategic technological roadmap, many retail investors are expressing caution due to high IPO pricing and ongoing debates about the company's long-term commercial revenue scaling compared to sector peers.

TOSHI

TOSHI is trending as investors speculate on potential ecosystem upgrades and cross-chain integrations while closely monitoring technical chart patterns for a possible breakout. Community sentiment remains polarized, with many long-term holders actively accumulating shares in anticipation of a significant price rally fueled by potential exchange listings and increased utility.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing intense community debate, with bulls citing potential ecosystem growth and institutional interest as catalysts for a long-term breakout, while bears express skepticism regarding recent project leadership updates and lack of clear token utility. The conversation remains polarized as investors weigh the asset's high-risk profile against the broader volatility affecting the crypto sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of […]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in a recent article that discussed its advancement of its proprietary multiple sclerosis therapy candidate, LUCID-MS, which is designed to target demyelination and protection or restoration of myelin integrity. The company reported that Phase 1 […]

Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma&#160;(NASDAQ: QNTM) (CSE: QNTM)&#160;is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. QNTM was highlighted in a recent article discussing its advancement of a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is […]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection, rigorous data collection and ongoing regulatory oversight, all in pursuit of a single goal —&#160;generating reliable evidence that a new drug, [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), was featured in a BioMedWire editorial highlighting its development of Lucid-MS, a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis. Unlike conventional MS treatments that primarily target the [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray [&#8230;]

Why Did QNTM Stock Pop In Pre-Market Today?

Equity

The biotech company signed a binding agreement with Allucent to support a planned Phase 2 trial to treat multiple sclerosis.

Quantum BioPharma Targets MS Progression with Novel Demyelination Therapy in Phase 2 Push

Quantum BioPharma (NASDAQ:QNTM) is taking a meaningful step forward in its clinical ambitions, signing a binding letter of intent with Allucent to advance its lead multiple sclerosis candidate, Lucid-21-302 (Lucid-MS), into a Phase 2 trial. The agreement signals more than operational progress, it reflects a broader push to bring differentiated, next-generation therapies into a market that remains heavily underserved despite decades of innovation.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM INVESTOR ALERT: Pomerantz Law Firm...

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.99
Prev Close	$2.84
Open	$2.86
Dividend Yield	0.00%
50-Day Moving Average	$4.53
Beta	1.22
Avg. Volume	265,111.88
PE Ratio	-0.36

52-Week High	$31.91
52-Week Low	$2.07
Market Capitalization	$19.13M
EPS (Annual)	-$7.97
Price to Book	29.41
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

QNTMQuantum BioPharma Ltd

Latest QNTM News